Drug Trial Radar · NCT05027568
A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 28, 2021
Primary completion
Sep 7, 2021
Study completion Sep 7, 2021
Sponsor
- Lead sponsor
- iOncturaIndustry
- Sponsor type
- Industry
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of Part 1 of this First-in-Human trial is to evaluate the safety and tolerability after single ascending oral doses of IOA-289 given to healthy male subjects, compared to placebo. After the oral dose administrations, the amount of IOA-289 present in serum will be determined for pharmacokinetic characterisation. Also the reduction of LPA in plasma will be determined as a pharmacodynamic biomarker. Part 2 is optional and its conduct will be dependent on the pharmacokinetic data generated in Part 1. Part 2 will be a randomized, crossover, open label, single oral dose administration of IOA-289 to healthy male subjects either in a fasted state, or after a high-fat meal.
Conditions
- Healthy
Interventions
IOA-289Drug
Daily oral twice daily dosing of IOA-289
Nab paclitaxel / gemcitabineDrug
Given in combination with IOA-289
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numbers of participants with treatment-related adverse events as assessed by MedDRA v24Time frame: Day 1: Predose and at 0.5,1, 2, 4, 8, 10 and 24 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centro Ricerche Cliniche di Verona srl
Verona, Verona, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.